ImageneBio, Inc. Common Stock (IMA) Stock Price

IMAStock
$4.04−46.77%52W
Market Cap$45.86M
P/E—
PEG Ratio—
Div yield—
Beta0.88

IMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.40%
Price vs S&P 500 (4W)-14.68%
VGM Score23.79

IMA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.98-$0.63+35.50%(+$0.35)
Q1 2026-$0.66-$0.95-43.94%(-$0.29)
Q3 2025-$1.00-$2.91-191.00%(-$1.91)
Q2 2025—-$4.46—

IMA Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.86
3.86
3.86
3.88

Industry Peers — Biological Products(186)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
IMAImageneBio, Inc. Common Stock
—FC5.0x———$4.04
AMGNAmgen IncDCA6.1x9.1%74.3%2.9%$432.49
GILDGilead Sciences IncCBA6.4x5.5%79.6%133.6%$156.19
MRNAModerna, Inc. Common StockFCA39.1x-27.6%36.4%—$218.01
ARGXargenx SE American Depositary SharesDAB6.6x165.2%89.8%—$819.14
RVMDRevolution Medicines, Inc. Common StockF—B3296.2x———$177.96
BIIBBiogen Inc. Common StockCDA3.4x0.3%74.0%-18.8%$232.65
BNTXBioNTech SE American Depositary ShareCCC7.6x-11.8%79.2%—$87.71
EXELExelixis IncCBA6.3x9.2%96.5%31.1%$62.23
HALOHalozyme Therapeutics, Inc.DBA8.3x41.1%82.4%22.9%$121.84
NBIXNeurocrine Biosciences IncCBB4.1x34.4%98.0%2.3%$135.71

About ImageneBio, Inc. Common Stock

ImageneBio is a clinical-stage biopharmaceutical company developing treatments for immunological and inflammatory diseases. Its lead candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody being evaluated for atopic dermatitis.